These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12885108)

  • 1. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.
    Page RL; Gozansky WS; Ruscin JM
    Pharmacotherapy; 2003 Jul; 23(7):945-54. PubMed ID: 12885108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinedione-induced congestive heart failure.
    Cheng AY; Fantus IG
    Ann Pharmacother; 2004 May; 38(5):817-20. PubMed ID: 15039476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.
    Granberry MC; Hawkins JB; Franks AM
    Am J Health Syst Pharm; 2007 May; 64(9):931-6. PubMed ID: 17468147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do thiazolidinediones cause heart failure? A critical review.
    Tang WH
    Cleve Clin J Med; 2006 Apr; 73(4):390-7. PubMed ID: 16610400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone and heart failure: long-term vigilance.
    Singh N
    J Cardiovasc Pharmacol Ther; 2004 Mar; 9(1):21-5. PubMed ID: 15094965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone-induced anasarca without heart failure: capillary leakage?
    Dagdelen S; Kurt M; Aydin K; Bayraktar M
    Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
    Berthet S; Olivier P; Montastruc JL; Lapeyre-Mestre M
    BMC Clin Pharmacol; 2011 May; 11():5. PubMed ID: 21609444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.
    Mudaliar S; Chang AR; Henry RR
    Endocr Pract; 2003; 9(5):406-16. PubMed ID: 14583425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations for management of fluid dynamic issues associated with thiazolidinediones.
    Hollenberg NK
    Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS
    Am J Health Syst Pharm; 2007 Dec; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract]   [Full Text] [Related]  

  • 13. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
    Lago RM; Singh PP; Nesto RW
    Lancet; 2007 Sep; 370(9593):1129-36. PubMed ID: 17905165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
    Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinedione-associated congestive heart failure and pulmonary edema.
    Kermani A; Garg A
    Mayo Clin Proc; 2003 Sep; 78(9):1088-91. PubMed ID: 12962163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.